Clinical trial Recruiting at 1 site Interventional Ages 35 to 65

Hypertension risk-based precision intervention in high-risk adults in Shunyi

Official title: A Multicenter, Parallel-Group, Community Cluster-Randomized Controlled Trial of a Hypertension Risk Model-Based Precision Intervention for Adults at High Risk of Hypertension in Shunyi District, Beijing, China

Run by Peking University · NCT07804420 · Data updated 2026-11-12

This community trial tests whether a WeChat-based, personalized health plan can help adults 35–65 at high risk for hypertension avoid developing it.

Quick facts

Study typeInterventional
Ages35 Years to 65 Years
SexAll
Enrollment500 (estimated)
SponsorPeking University
Academic / other
Locations1 site (Beijing, Beijing Municipality)
StatusRecruiting
StartedApril 1, 2026
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedSeptember 16, 2026
Trial IDNCT07804420 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 35–65 in Shunyi District identified as high risk for hypertension (predicted risk >20%), without current hypertension or antihypertensive medications, and able to use WeChat.

Probably not a fit

Individuals with normal or low baseline risk or who are already receiving antihypertensive treatment are unlikely to benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, cluster-randomized trial in Shunyi District assigns four communities to either a hypertension risk model–based precision intervention or usual care. Participants are adults aged 35–65 with a predicted hypertension risk over 20% who are not yet diagnosed with hypertension and not on blood pressure medicines. The intervention uses a WeChat mini-program and local healthcare providers to deliver personalized education, goal setting, follow-up, blood pressure monitoring guidance, and health management tools, with follow-ups at 1, 3, and 6 months. The study aims to determine if targeted behavioral and management strategies can reduce the transition from high-risk status to hypertension compared with standard health education. Randomization occurs at the community cluster level, not at the individual level.

Why it matters

Potential benefit: If successful, participants may lower their risk of developing hypertension through personalized guidance and regular monitoring.

How similar studies have gone: Previous similar approaches using risk-prediction models and digital health coaching have shown promise in improving blood pressure behaviors, though cluster-randomized evidence in this specific setting is limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Aged 35 to 65 years. Permanent resident of Shunyi District, Beijing, China. Identified as being at high risk of developing hypertension through the Hypertension Risk Assessment WeChat mini-program, with a predicted hypertension risk greater than 20%.

No current diagnosis of hypertension, with systolic blood pressure \<140 mmHg and diastolic blood pressure \<90 mmHg, and not currently taking antihypertensive medication.

Willing to participate in the study and able to provide written informed consent.

Owns a smartphone and is able to use basic WeChat functions.

Exclusion Criteria:

Previously diagnosed hypertension or current use of antihypertensive medications.

History of serious cardiovascular or cerebrovascular disease, such as myocardial infarction or stroke.

Severe hepatic or renal dysfunction, malignant tumor, serious psychiatric disorder, or other serious disease.

Planning to move out of Shunyi District within the next 9 months. Currently participating in another similar intervention study.

Where it's running

  • Shunyi District Center for Disease Control and Prevention, Beijing
    Beijing, Beijing Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.